New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
07:07 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol, or CBD, for the treatment of glioblastoma multiforme, or GBM, the most common and most aggressive malignant primary brain tumor in humans. In addition to receiving orphan drug designation, Insys has recently entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute, or CPMCRI, based in San Francisco to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:04 EDTINSYInsys Therapeutics receives FDA orphan drug designation to CBD candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use